PHILADELPHIA, Feb. 5, 2025
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma"
or the "Company"), a leader in macrophage-focused therapeutics,
today announced that Steven Kelly,
President and Chief Executive Officer, will participate in the
Oppenheimer 35th Annual Healthcare Life Sciences
Conference on Tuesday, February 11 at
4:40 pm ET.
An audio webcast of the event will be available on the
Company's Investor Events section of the Investor
Relations webpage and will be archived for a limited time following
the event.
About Carisma
Carisma Therapeutics is a biopharmaceutical Company pioneering
macrophage engineering to develop groundbreaking therapies for
fibrosis, cancer, and other diseases. With a strong commitment to
patient-centric innovation, Carisma aims to deliver scalable,
next-generation solutions that transform treatment paradigms.
Carisma is headquartered in Philadelphia, PA. For more
information, please visit www.Carismatx.com.
Investors:
Shveta
Dighe
investors@carismatx.com
Media Contact:
Julia
Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-oppenheimer-35th-annual-healthcare-life-sciences-conference-302367990.html
SOURCE Carisma Therapeutics Inc.
